COMUNICADO: European Commission Approves New Pre-treatment Options for QUTENZA(TM) (8% Capsaicin Patch) in Peripheral Neuropathic Pa

Actualizado 14/03/2013 11:47:40 CET

5. Simpson DM et al. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008;70(24):2305-13

6. O'Connor AB et al. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009;122:S22-32

7. Qutenza (Capsaicin) EPAR. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- Product_Information/human/000909/WC500040453.pdf Last accessed: March 2013.

8. Gilron I et al. Neuropathic pain: a practical guide for the clinician. CMAJ 2006;175(3):265-75

9. Mailis Gagnon A et al. Systematic review of the prevalence of neuropathic pain. Eur J Pain 2007;11 (Suppl. 1):S202-S203 [Abstract No. 457]

10. National Institute for Health and Clinical Excellence (NICE) Neuropathic Pain: The pharmacological management of neuropathic pain in adults in non-specialist settings. March 2010. Available from: http://www.nice.org.uk/nicemedia/live/12948/47949/47949.pdf Last accessed: November 2012

11. Gálvez R et al. Cross-sectional evaluation of patient functioning and health-related quality of life in patient with neuropathic pain under standard care conditions. Eur J of Pain 2007;3:244-55

12. Smith B et al. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain 2007;23:143-9

13. Jensen T et al. Pharmacology and treatment of neuropathic pains. Current Opinion in Neurology 2009;22:467-474

14. Hansson P et al. A Swedish prospective observational multicenter study to evaluate efficacy and safety in patients with peripheral neuropathic pain receiving their first Qutenza(TM) treatment." Presented at World Congress on Pain, Milan, August 2012 [Abstract PT 422]

15. Klimes J et al. High concentration (8%) of capsaicin patch: Effectiveness in real clinical practice for treatment of neuropathic pain of non-diabetic etiology in the Czech Republic. Presented at World Congress on Pain, Milan, August 2012 [Abstract PH 107]

16 . Bhaskar A et al. Chemotherapy-induced painful neuropathy: treatment with the capsaicin 8% patch. Presented at European Association for Palliative Care, Norway, June 7 - 9, 2012 [Poster 466]

17. Bhaskar A et al. Management of neuropathic pain (NP) using the capsaicin 8% patch in patients with cancer. . Presented at European Association for Palliative Care, Norway, June 7 - 9, 2012 [Poster 465]

18. EU Clinical Trials Register: https://www.clinicaltrialsregister.eu/ctr-search/search?query=E05-CL-3002 Full Download. Last accessed: November 2012

19. ClinicalTrials.gov: http://www.clinicaltrials.gov/ct2/results?term=NCT01478607 Last accessed: November 2012

20. Wagner T, Roth-Daniek A, Poole C. Reduction In Concomitant Neuropathic Pain (Np) Medication Use After Treatment With The Capsaicin 8% Patch: A Retrospective Analysis. 7th Congress of the European Federation of IASP Chapters (EFIC), September 21-24, 2011. Abstract 469

21. Dolezal T et al. High concentration capsaicin patch improves quality of life in patients with neuropathic non-diabetic pain. Presented at World Congress on Pain, Milan, August 2012 [Abstract PH 124]

22. Vocelka M et al. Lower consumption of concomitant pain medication and other resource use after administration of 8% capsaicin patch: Results of the observational study. Presented at World Congress on Pain, Milan, August 2012 [Abstract PH 135]

23. Knotkova H et al. Capsaicin (TRPV1 agonist) therapy for pain relief: Farewell or revival? Clin J Pain 2008;24(2):142- 154

24. Anand P et al. Topical capsacin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8%

CONTACT: Contacts for enquiry or additional information: Astellas PharmaEurope Ltd.: Mindy Dooa, Tel: +44-(0)203-379-8035 / +44-(0)7826-912-339,mindy.dooa@astellas.com; Pegasus: Sylva Michelli, Tel: +44-(0)1903-836745 /+44-(0)7507-598-427, smichelli@pegasuspr.co.uk

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación

Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies